http://purl.org/np/RAf3jaL2Fc... RAf3jaL2Fc

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#type type

http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement Statement

Leoni Bücken

2021-06-12T11:08:20.700Z

http://purl.org/np/RAf3jaL2Fc... RAf3jaL2Fc

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/2000/01/rdf-schema#label label

genotropin is a recombinant human growth hormone indicated for pediatric 1 1 adult 1 2 genotropin is indicated for the treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone genotropin is indicated for the treatment of pediatric patients who have growth failure due to prader willi syndrome pws the diagnosis of pws should be confirmed by appropriate genetic testing see contraindications 4 genotropin is indicated for the treatment of growth failure in children born small for gestational age sga who fail to manifest catch up growth by age 2 years genotropin is indicated for the treatment of growth failure associated with turner syndrome genotropin is indicated for the treatment of idiopathic short stature iss also called non growth hormone deficient short stature defined by height standard deviation score sds 2 25 and associated with growth rates unlikely to permit attainment of adult height in the normal range in pediatric patients whose epiphyses are not closed and for whom diagnostic evaluation excludes other causes associated with short stature that should be observed or treated by other means genotropin is indicated for replacement of endogenous growth hormone in adults with growth hormone deficiency who meet either of the following two criteria adult onset ao childhood onset co patients who were treated with somatropin for growth hormone deficiency in childhood and whose epiphyses are closed should be reevaluated before continuation of somatropin therapy at the reduced dose level recommended for growth hormone deficient adults according to current standards confirmation of the diagnosis of adult growth hormone deficiency in both

Leoni Bücken

2021-06-12T11:08:20.700Z

http://purl.org/np/RAf3jaL2Fc... RAf3jaL2Fc

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#object object

http://purl.obolibrary.org/obo/DOID_11983 DOID_11983

Leoni Bücken

2021-06-12T11:08:20.700Z

http://purl.org/np/RAf3jaL2Fc... RAf3jaL2Fc

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate predicate

https://w3id.org/biolink/vocab/treats treats

Leoni Bücken

2021-06-12T11:08:20.700Z

http://purl.org/np/RAf3jaL2Fc... RAf3jaL2Fc

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#subject subject

https://identifiers.org/drugbank:DB00052 drugbank:DB00052

Leoni Bücken

2021-06-12T11:08:20.700Z

http://purl.org/np/RAf3jaL2Fc... RAf3jaL2Fc

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/association_type association_type

https://w3id.org/biolink/vocab...OrPhenotypicFeatureAssociation ChemicalToDiseaseOrPhenotypicFeatureAssociation

Leoni Bücken

2021-06-12T11:08:20.700Z

http://purl.org/np/RAf3jaL2Fc... RAf3jaL2Fc

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/provided_by provided_by

https://w3id.org/um/NeuroDKG NeuroDKG

Leoni Bücken

2021-06-12T11:08:20.700Z

http://purl.org/np/RAf3jaL2Fc... RAf3jaL2Fc

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/relation relation

https://w3id.org/um/neurodkg/SymptomaticReliefIndication SymptomaticReliefIndication

Leoni Bücken

2021-06-12T11:08:20.700Z